Ascendis Pharma A/S American Depositary Shares

Ascendis Pharma received notification from the FDA extending the PDUFA target action date for TransCon CNP by three months to February 28, 2026, after submitting additional information for their New Drug Application for treating children with achondroplasia.

BioMarin Pharmaceutical reported strong Q4 earnings, beating consensus estimates for both EPS and revenue. The company provided upbeat 2025 guidance, expecting sales of $3.1-$3.2 billion and EPS of $4.20-$4.40.

Ascendis Pharma, a biotech company, reported a revenue miss and reduced guidance for its key product Skytrofa, leading to an over 11% drop in its stock price.

The FDA is expected to make several landmark decisions in Q3, including approvals for treatments for schizophrenia, PTSD, and liver disease. These decisions could be impacted by recent biotechnology acquisitions.

In our monthly Rare Stock Picks series, we're highlighting May 2024 investment picks. Click here for the list of May 2024 Buy recommendations.